Related references
Note: Only part of the references are listed.CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Kristen Fousek et al.
LEUKEMIA (2021)
Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Manon Queudeville et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
Julia Ruark et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Acute Kidney Injury: Diagnosis and Management
Jean-Philippe Roy et al.
INDIAN JOURNAL OF PEDIATRICS (2020)
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma
Shruti Gupta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Susan E Prockop et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study
Susan E Prockop et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
Victoria Gutgarts et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer
Cristina Gutierrez et al.
CRITICAL CARE MEDICINE (2020)
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
Susan Prockop et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020
Patrick Brown et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
Birgit Geoerger et al.
LANCET ONCOLOGY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
Francesco Lanza et al.
CANCERS (2020)
Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach
Jeanne de La Rochefoucauld et al.
INTERNAL AND EMERGENCY MEDICINE (2020)
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
Kris M. Mahadeo et al.
LANCET HAEMATOLOGY (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial
Kara L. Davis et al.
LANCET ONCOLOGY (2020)
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2020)
Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma
Soumen Khatua et al.
NEURO-ONCOLOGY (2020)
ICU Resource Use in Critically Ill Patients following Chimeric Antigen Receptor T-Cell Therapy
Anne Rain T. Brown et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Joshua A. Hill et al.
BLOOD (2020)
SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis
Abbas Mohammadi et al.
EBIOMEDICINE (2020)
CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
Yongxian Xu et al.
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2020)
The chimeric antigen receptor -intensive care unit (CAR -ICU) initiative: Surveying intensive care unit practices in the management of CAR T -cell associated toxicities
Cristina Gutierrez et al.
JOURNAL OF CRITICAL CARE (2020)
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Reuben Benjamin et al.
LANCET (2020)
Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients
Mira A. Kohorst et al.
ECLINICALMEDICINE (2020)
Clinical Characteristics and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italian Pediatric Oncology Patients: A Study From the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica
Gianni Bisogno et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)
Clinical burden of immune checkpoint inhibitor-induced pneumonitis
Koji Sakamoto et al.
RESPIRATORY INVESTIGATION (2020)
Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020
Shruti Gupta et al.
KIDNEY360 (2020)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
Linh T. Nguyen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
Rosa Nguyen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy
Juliane Gust et al.
ANNALS OF NEUROLOGY (2019)
EARLY ADMINISTRATION OF TOCILIZUMAB (TOCI) FOR THE PREVENTION OF GRADE 4 CYTOKINE RELEASE SYNDROME (CRS) AFTER CD19-DIRECTED CAR T-CELL THERAPY (CTL019)
S. Kadauke et al.
CYTOTHERAPY (2019)
Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment
Kentaro Masuhiro et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity
Regina E. M. Baiden-Amissah et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers
Maria R. Parkhurst et al.
CANCER DISCOVERY (2019)
Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile
Qingnan Zhao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function
Marina Olle Hurtado et al.
PLOS ONE (2019)
The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers
Miriam Santiago Kimpo et al.
CURRENT ONCOLOGY REPORTS (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Jean-Christophe Pignon et al.
CLINICAL CANCER RESEARCH (2019)
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Jay A. Fishman et al.
CLINICAL INFECTIOUS DISEASES (2019)
Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
Yi-He Liu et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Rebecca A. Gardner et al.
BLOOD (2019)
Patterns of Use of Heated Humidified High-Flow Nasal Cannula Therapy in PICUs in the United Kingdom and Republic of Ireland*
Jenny V. Morris et al.
PEDIATRIC CRITICAL CARE MEDICINE (2019)
Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity Be Aware and Prepared
Elie Azoulay et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines
Saralinh Trinh et al.
ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING (2019)
Genetically engineered T cells for cancer immunotherapy
Dan Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Vera Dufner et al.
BLOOD ADVANCES (2019)
CAR T Cell Toxicity: Current Management and Future Directions
Lucrecia Yanez et al.
HEMASPHERE (2019)
Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events
Kenji Ihara
CLINICAL PEDIATRIC ENDOCRINOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia
M. Vela et al.
CANCER LETTERS (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)
G. Redelman-Sidi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki Stamatouli et al.
DIABETES (2018)
Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer
Salman M. Toor et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
Albumin infusion improves endothelial function in septic shock patients: a pilot study
Geoffroy Hariri et al.
INTENSIVE CARE MEDICINE (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus
Katrien Clotman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Do immune checkpoint inhibitors need new studies methodology?
Roberto Ferrara et al.
JOURNAL OF THORACIC DISEASE (2018)
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
Sawsan Rashdan et al.
LANCET RESPIRATORY MEDICINE (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
John E. Mullinax et al.
FRONTIERS IN ONCOLOGY (2018)
Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy
Muharrem Muftuoglu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
Profile of Capillary-Leak Syndrome in Patients Received Chimeric Antigen Receptor T Cell Therapy
Yongxian Hu et al.
BLOOD (2018)
Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma
Milcah C. Scott et al.
CANCER RESEARCH (2018)
Driving gene-engineered T cell immunotherapy of cancer
Laura A. Johnson et al.
CELL RESEARCH (2017)
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
Birgit Geoerger et al.
EUROPEAN JOURNAL OF CANCER (2017)
BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation
Oscar M. Pello et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Update on the use of immunoglobulin in human disease: A review of evidence
Elena E. Perez et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report
Xiao Zhu et al.
JOURNAL OF NEUROSURGERY-PEDIATRICS (2017)
Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma
Alexandra E. Foran et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2017)
The Relationship between High Flow Nasal Cannula Flow Rate and Effort of Breathing in Children
Thomas Weiler et al.
JOURNAL OF PEDIATRICS (2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy
Maximilian J. Hochmair et al.
LUNG CANCER (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS
Isao Tawara et al.
BLOOD (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Melinda S. Merchant et al.
CLINICAL CANCER RESEARCH (2016)
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Andrew C. Harris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
Deborah T. Blumenthal et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression
Junko Tanizaki et al.
LUNG CANCER (2016)
Urinary biomarker incorporation into the renal angina index early in intensive care unit admission optimizes acute kidney injury prediction in critically ill children: a prospective cohort study
Shina Menon et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Marco Ruella et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL
Shannon L. Maude et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Shannon L. Maude et al.
BLOOD (2016)
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner
L. Fernandez et al.
CANCER LETTERS (2015)
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Alan Serrels et al.
CELL (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Heated humidified high-flow nasal cannula therapy in children
F. A. Hutchings et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2015)
Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation
Nirali N. Shah et al.
BLOOD (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Bispecific T-cell engagers for cancer immunotherapy
Amelia M. Huehls et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma
Andrea Schuessler et al.
CANCER RESEARCH (2014)
Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Thinle Chodon et al.
CLINICAL CANCER RESEARCH (2014)
Low-flow oxygen: How much is your patient really getting?
Christine F. McDonald
RESPIROLOGY (2014)
High-flow nasal cannula: recommendations for daily practice in pediatrics
Christophe Milesi et al.
ANNALS OF INTENSIVE CARE (2014)
A national approach to improving adolescent and young adult (AYA) oncology psychosocial care: The development of AYA-specific psychosocial assessment and care tools
Susan Palmer et al.
PALLIATIVE & SUPPORTIVE CARE (2014)
Harnessing the Power of the Immune System to Target Cancer
Gregory Lizee et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
Ann M. Leen et al.
BLOOD (2013)
Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Yan Feng et al.
CLINICAL CANCER RESEARCH (2013)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Richard A. Morgan et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors
Antonio Perez-Martinez et al.
EXPERIMENTAL HEMATOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Progressive multifocal leukoencephalopathy
Robert Weissert
JOURNAL OF NEUROIMMUNOLOGY (2011)
ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia
H. Elizabeth Broome et al.
LEUKEMIA RESEARCH (2011)
Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients
Paivi M. Miettunen et al.
RHEUMATOLOGY (2011)
Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells
Andreas Moosmann et al.
BLOOD (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors
Duck Cho et al.
CLINICAL CANCER RESEARCH (2010)
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
Jeffrey E. Rubnitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
Marcie Tomblyn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197-conjugated serogroup C meningococcal polysaccharide vaccine
Dominic F. Kelly et al.
IMMUNOLOGY (2009)
The Utility of Simulation in Medical Education: What is the Evidence?
Yasuharu Okuda et al.
MOUNT SINAI JOURNAL OF MEDICINE (2009)
Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma
Steven Yeh et al.
OPHTHALMOLOGY (2009)
Research in high flow therapy: Mechanisms of action
Kevin Dysart et al.
RESPIRATORY MEDICINE (2009)
Acute graft-versus-host disease in children
D. A. Jacobsohn
BONE MARROW TRANSPLANTATION (2008)
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Jan-Inge Henter et al.
PEDIATRIC BLOOD & CANCER (2007)
Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study
Marc-Jacques Dubois et al.
CRITICAL CARE MEDICINE (2006)
Adoptive immunotherapy for cancer: building on success
L Gattinoni et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Cytotoxic T cells
Mads Hald Andersen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
W Schwinger et al.
ANNALS OF ONCOLOGY (2005)
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes
KCM Straathof et al.
BLOOD (2005)
Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
CM Bollard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells
V Screpanti et al.
JOURNAL OF IMMUNOLOGY (2001)
Percentage of burned body surface area determination in obese and nonobese patients
EH Livingston et al.
JOURNAL OF SURGICAL RESEARCH (2000)
Share Paper
